|
Seropositivity rates and GMTs for anti-CS and Anti-HBs antibodies (ATP cohort for immunogenicity) |
|||||||||||
| Group |
Timing |
N |
Seropositives |
MIN |
MAX |
||||||
| 95% CI |
GMT |
95% CI |
|||||||||
| n |
% |
LL |
UL |
LL |
UL |
||||||
|
|
|||||||||||
| GMTs anti-CS antibodies (EU/mL) |
|||||||||||
|
|
|||||||||||
| RTS, S/AS02D |
Pre |
67 |
9 |
13,4 |
6,3 |
24 |
0,3 |
0,3 |
0,4 |
< 0,5 |
8 |
| PIII(M3) |
67 |
67 |
100 |
94,6 |
100 |
191 |
150 |
242 |
14 |
1314 |
|
| PIII(M14) |
60 |
60 |
100 |
94 |
100 |
22 |
15 |
32 |
0,5 |
543 |
|
|
|
|||||||||||
| RTS, S/AS02A |
Pre |
76 |
10 |
13,2 |
6,5 |
22,9 |
0,3 |
0,3 |
0,4 |
< 0,5 |
8 |
| PIII(M3) |
76 |
76 |
100 |
95,3 |
100 |
180 |
146 |
221 |
16 |
1277 |
|
| PIII(M14) |
67 |
67 |
100 |
94,6 |
100 |
29 |
22 |
39 |
1 |
323 |
|
|
|
|||||||||||
| GMTs anti-HBs antibodies (mIU/mL) |
|||||||||||
|
|
|||||||||||
| RTS, S/AS02D |
Pre |
67 |
6 |
9,0 |
3,4 |
18,5 |
8 |
5 |
11 |
< 10 |
2211 |
| PIII(M3) |
67 |
67 |
100 |
94,6 |
100 |
23978 |
17896 |
32127 |
985 |
446880 |
|
| PIII(M14) |
60 |
60 |
100 |
94,0 |
100 |
5184 |
4043 |
6646 |
653 |
100110 |
|
|
|
|||||||||||
| RTS, S/AS02A |
Pre |
76 |
5 |
6,6 |
2,2 |
14,7 |
6 |
5 |
8 |
< 10 |
1759 |
| PIII(M3) |
76 |
76 |
100 |
95,3 |
100 |
17410 |
13322 |
22752 |
1265 |
823500 |
|
| PIII(M14) |
66 |
66 |
100 |
94,6 |
100 |
5024 |
3918 |
6443 |
877 |
260700 |
|
|
N: number of subjects with available results; GMT: geometric mean antibody titer calculated on all subjects; MIN/MAX: Minimum/Maximum; n (%): number (percentage) of subjects with titer ≥ 0.5 EU/mL for Anti-CS or with titer ≥ 10 mIU/mL for Anti-HBsAg; 95% CI: 95% confidence interval; LL: Lower Limit, UL: Upper Limit; Pre: Pre-vaccination; PIII(M3): blood sampling taken 3 months after the first dose of vaccine; PIII(M14): blood sampling taken 14 months after the first dose of vaccine | |||||||||||
Macete et al. Trials 2007 8:11 doi:10.1186/1745-6215-8-11 |
|||||||||||